Inpharmatica Announces Collaboration Agreement with Ingenuity
News Mar 21, 2006
Inpharmatica Ltd has announced a collaboration agreement with Ingenuity Systems, Inc, Redwood City, California. Under the terms of the agreement, the two companies will work together to bring their customers the benefits of using in tandem two advanced and independently-developed drug discovery tools.
A major benefit of the agreement is that researchers working with the Affymetrix GeneChips will be able access world-class knowledge-bases that cover all aspects of research from initial probe assignment to details of the protein network.
The two products are Inpharmatica's probe to protein assignment module; Blu-Chip™ and Ingenuity's Pathway Analysis (IPA). Blu-Chip and IPA are different types of solutions designed to facilitate work in a number of research areas.
Inpharmatica's Blu-Chip™ is designed to offer biologists an essential resource for resolving probe to protein assignments, maximizing the value of GeneChip® experiments.
With Blu-Chip, researchers access a knowledgebase of preferred and alternative assignments. An intuitive interface enables them to resolve ambiguity and build valued judgements.
Blu-Chip is particularly effective at distinguishing splice variants and isoforms, as well as providing clear indications of intronic location.
Ingenuity Pathways Analysis is a web-delivered software application that is designed to enable researchers to model, analyze and understand the complex biological systems at the core of life science research.
IPA is deployed in most major pharmaceutical companies and hundreds of biotechnology companies and academic institutions globally.
It supports analysis of high throughput analysis platforms and is used in virtually all areas of drug discovery and development from target identification and validation to biomarkers, predictive toxicology, and pharmacogenomics.
"Ingenuity's IPA software has garnered favorable opinions throughout the research community, and we look forward to an effective partnership with the company," said John Lisle, CEO of Inpharmatica.
"This is Inpharmatica's first collaboration of this kind and we believe that it will prove a huge success as it enables researchers to move seamlessly through two key steps of analysis - probe assignment and protein network analysis - thus simplifying workflows and accelerating discoveries."
"Inpharmatica is an established player in the field of drug discovery technologies and services and we are excited to be working with them," said Tuan Nguyen, Vice President of Partner and Professional Services, of Ingenuity Systems.
"The synergy provided by offering Blu-Chip and IPA together will bring benefits to our users in the research community and to the two companies themselves - a win-win for all concerned."
In new studies a novel oxygen-delivery therapeutic restored the function of oxygen-starved heart tissue in an animal model of global hypoxia. Unlike its experimental predecessors, the new drug does not appear to cause systemic side effects or overcorrect with excessive blood oxygenation, which can itself be toxic. Instead, the new drug delivers its precious oxygen cargo only to the tissues that need it most.READ MORE
Previous work by the International Multiple Sclerosis Genetics Consortium (IMSGC) has identified 233 genetic risk variants. However, these only account for about 20% of overall disease risk, with the remaining genetic culprits proving elusive. A new study has tracked down four of these hard-to-find genes.READ MORE
The sweet flavors’ appeal to teens is a major concern for Food and Drug Administration officials, who recently declared teen vaping an epidemic. New research shows flavorings are transforming more than marketing. The chemical additives react to e-liquid, or e-juice, creating new compounds that could trigger irritation and inflammation when inhaled.READ MORE